Literature DB >> 8709207

In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype.

R B Roden1, H L Greenstone, R Kirnbauer, F P Booy, J Jessie, D R Lowy, J T Schiller.   

Abstract

We report a system for generating infectious papillomaviruses in vitro that facilitates the analysis of papillomavirus assembly, infectivity, and serologic relatedness. Cultured hamster BPHE-1 cells harboring autonomously replicating bovine papillomavirus type 1 (BPV1) genomes were infected with recombinant Semliki Forest viruses that express the structural proteins of BPV1. When plated on C127 cells, extracts from cells expressing L1 and L2 together induced numerous transformed foci that could be specifically prevented by BPV neutralizing antibodies, demonstrating that BPV infection was responsible for the focal transformation. Extracts from BPHE-1 cells expressing L1 or L2 separately were not infectious. Although Semliki Forest virus-expressed L1 self-assembled into virus-like particles (VLPs), viral DNA was detected in particles only when L2 was coexpressed with L1, indicating that genome encapsidation requires L2. Expression of human papillomavirus type 16 (HPV16) L1 and L2 together in BPHE-1 cells also yielded infectious virus. These pseudotyped virions were neutralized by antiserum to HPV16 VLPs derived from European (114/K) or African (Z-1194) HPV16 variants but not by antisera to BPV VLPs, to a poorly assembling mutant HPV16 L1 protein, or to VLPs of closely related genital HPV types. Extracts from BPHE-1 cells coexpressing BPV L1 and HPV16 L2 or HPV16 L1 and BPV L2 were not infectious. We conclude that (i) mouse C127 cells express the cell surface receptor for HPV16 and are able to uncoat HPV16 capsids; (ii) if a papillomavirus DNA packaging signal exists, then it is conserved between the BPV and HPV16 genomes; (iii) functional L1-L2 interaction exhibits type specificity; and (iv) protection by HPV virus-like particle vaccines is likely to be type specific.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709207      PMCID: PMC190605          DOI: 10.1128/JVI.70.9.5875-5883.1996

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

Review 1.  Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types.

Authors:  H zur Hausen
Journal:  Curr Top Microbiol Immunol       Date:  1994       Impact factor: 4.291

2.  Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells.

Authors:  C Volpers; P Schirmacher; R E Streeck; M Sapp
Journal:  Virology       Date:  1994-05-01       Impact factor: 3.616

3.  Semliki Forest virus expression system: production of conditionally infectious recombinant particles.

Authors:  P Berglund; M Sjöberg; H Garoff; G J Atkins; B J Sheahan; P Liljeström
Journal:  Biotechnology (N Y)       Date:  1993-08

4.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

5.  Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden.

Authors:  P Pisani; D M Parkin; J Ferlay
Journal:  Int J Cancer       Date:  1993-12-02       Impact factor: 7.396

6.  Interaction of papillomaviruses with the cell surface.

Authors:  R B Roden; R Kirnbauer; A B Jenson; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

7.  Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence.

Authors:  J Zhou; X Y Sun; K Louis; I H Frazer
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

8.  Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles.

Authors:  R C Rose; W Bonnez; C Da Rin; D J McCance; R C Reichman
Journal:  J Gen Virol       Date:  1994-09       Impact factor: 3.891

9.  Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins.

Authors:  R B Roden; E M Weissinger; D W Henderson; F Booy; R Kirnbauer; J F Mushinski; D R Lowy; J T Schiller
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

10.  Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies.

Authors:  N D Christensen; R Höpfl; S L DiAngelo; N M Cladel; S D Patrick; P A Welsh; L R Budgeon; C A Reed; J W Kreider
Journal:  J Gen Virol       Date:  1994-09       Impact factor: 3.891

View more
  111 in total

1.  DNA-induced structural changes in the papillomavirus capsid.

Authors:  C Fligge; F Schäfer; H C Selinka; C Sapp; M Sapp
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.

Authors:  R B Roden; P M Day; B K Bronzo; W H Yutzy; Y Yang; D R Lowy; J T Schiller
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 4.  Immunological memory ≠ protective immunity.

Authors:  Rolf M Zinkernagel
Journal:  Cell Mol Life Sci       Date:  2012-04-06       Impact factor: 9.261

5.  HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.

Authors:  Douglas R Lowy
Journal:  J Clin Invest       Date:  2016-01-04       Impact factor: 14.808

Review 6.  Prevention of cancer by prophylactic human papillomavirus vaccines.

Authors:  Kihyuck Kwak; Anna Yemelyanova; Richard B S Roden
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

7.  A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.

Authors:  Patricia M Day; Yuk-Ying S Pang; Rhonda C Kines; Cynthia D Thompson; Douglas R Lowy; John T Schiller
Journal:  Clin Vaccine Immunol       Date:  2012-05-16

8.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.

Authors:  Katherine M Johnson; Rhonda C Kines; Jeffrey N Roberts; Douglas R Lowy; John T Schiller; Patricia M Day
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

10.  Detection and quantitation of human papillomavirus by using the fluorescent 5' exonuclease assay.

Authors:  A Josefsson; K Livak; U Gyllensten
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.